pubmed.ncbi.nlm.nih.gov

The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion - PubMed

The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion

Ting-Hsu Chen et al. J Infect Public Health. 2023 Jan.

Abstract

Background: The novel coronavirus disease-2019 (COVID-19) that emerged in China, is an extremely contagious and pathogenic viral infection caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) that has sparked a global pandemic. The few and limited availability of approved therapeutic agents or vaccines is of great concern. Urgently, Remdesivir, Nirmatrelvir, Molnupiravir, and some phytochemicals including polyphenol, flavonoid, alkaloid, and triterpenoid are applied to develop as repurposing drugs against the SARS-CoV-2 invasion.

Methods: This study was conducted to perform molecular docking and absorption, distribution, metabolism, excretion and toxicity (ADMET) analysis of the potential phytocompounds and repurposing drugs against three targets of SARS-CoV-2 proteins (RNA dependent RNA polymerase, RdRp, Endoribonclease, S-protein of ACE2-RBD).

Results: The docking data illustrated Arachidonic acid, Rutin, Quercetin, and Curcumin were highly bound with coronavirus polyprotein replicase and Ebolavirus envelope protein. Furthermore, anti- Ebolavirus molecule Remedesivir, anti-HIV molecule Chloroquine, and Darunavir were repurposed with coronavirus polyprotein replicase as well as Ebolavirus envelope protein. The strongest binding interaction of each targets are Rutin with RdRp, Endoribonclease with Amentoflavone, and ACE2-RBD with Epigallocatechin gallate.

Conclusions: Taken altogether, these results shed a light on that phytocompounds have a therapeutic potential for the treatment of anti-SARS-CoV-2 may base on multi-target effects or cocktail formulation for blocking viral infection through invasion/activation, transcription/reproduction, and posttranslational cleavage to battle COVID-19 pandemic.

Keywords: Immune evasion; Phytocompounds; Remedesivir; SARS-CoV-2; Viral proliferation; Virus entry.

Copyright © 2022. Published by Elsevier Ltd.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest The authors declare no conflict of interest.

Figures

ga1
Graphical abstract
Fig. 1
Fig. 1

The 3D dock-mapping of clinic drug and chemicals at Ebolavirus envelope protein and the replicase of Coronavirus.

Fig. 2
Fig. 2

The 2D images of ligands-target protein interaction and 3D dock- superimpose mapping of candidate molecules with main(cyan) protease and COVID-19 PL (green) (Black: Squalene; Yellow: alpha-Tocopheryolquinone; Red: Darunavir; Purple: Vitamin E; Green: Remdesivir).

Similar articles

Cited by

References

    1. Trougakos I.P., Stamatelopoulos K., Terpos E., Tsitsilonis O.E., Aivalioti E., Paraskevis D., et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021;28:9. - PMC - PubMed
    1. Rohlfing A.K., Rath D., Geisler T., Gawaz M. Platelets and COVID-19. Hamostaseologie. 2021;41:379–385. - PubMed
    1. Elena S.F. Evolutionary transitions during RNA virus experimental evolution. Philos Trans R Soc Lond B Biol Sci. 2016;371 - PMC - PubMed
    1. Sola I., Almazan F., Zuniga S., Enjuanes L. Continuous and Discontinuous RNA Synthesis in Coronaviruses. Annu Rev Virol. 2015;2:265–288. - PMC - PubMed
    1. de Wilde A.H., Snijder E.J., Kikkert M., van Hemert M.J. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1–42. - PMC - PubMed

MeSH terms

Substances